Not surprisingly the minor structural differences between maprotiline and the TCAs have not resulted in any changes in the drug's cardiovascular pharmacologic profile when compared to the TCAs. Like the TCAs, it shows conduction delays at normal therapeutic doses and, in overdose, cardiovascular deaths associated
with heart block and asystole have been reported